Immunic (IMUX) News Today $0.89 +0.02 (+2.08%) Closing price 04:00 PM EasternExtended Trading$0.89 +0.01 (+0.76%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMUX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears UnwarrantedJune 9 at 6:04 PM | seekingalpha.comMillennium Management LLC Has $580,000 Stake in Immunic, Inc. (NASDAQ:IMUX)Millennium Management LLC grew its stake in Immunic, Inc. (NASDAQ:IMUX - Free Report) by 480.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 579,683 shares of the company's stock after purchasing an additional 479,June 9 at 3:22 AM | marketbeat.comImmunic completes Phase 3 multiple sclerosis trial enrollment - ICYMIJune 7 at 9:35 AM | proactiveinvestors.comQ2 Earnings Estimate for Immunic Issued By Leerink PartnrsJune 7 at 1:17 AM | americanbankingnews.comInsider Buying: Immunic, Inc. (NASDAQ:IMUX) CEO Purchases 15,000 Shares of StockImmunic, Inc. (NASDAQ:IMUX - Get Free Report) CEO Daniel Vitt bought 15,000 shares of the stock in a transaction on Wednesday, June 4th. The shares were acquired at an average cost of $0.77 per share, with a total value of $11,550.00. Following the acquisition, the chief executive officer now directly owns 29,000 shares in the company, valued at approximately $22,330. This trade represents a 107.14% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.June 6, 2025 | marketbeat.comImmunic completes patient enrollment in Phase 3 relapsing multiple sclerosis trialsJune 5, 2025 | proactiveinvestors.comD. Boral Capital Reiterates Buy Rating for Immunic (NASDAQ:IMUX)D. Boral Capital reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Immunic in a report on Thursday.June 5, 2025 | marketbeat.comImmunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MSJune 5, 2025 | prnewswire.comQ2 Earnings Forecast for Immunic Issued By Leerink PartnrsImmunic, Inc. (NASDAQ:IMUX - Free Report) - Equities research analysts at Leerink Partnrs lifted their Q2 2025 earnings per share (EPS) estimates for shares of Immunic in a report issued on Tuesday, June 3rd. Leerink Partnrs analyst F. Khurshid now forecasts that the company will post earnings peJune 5, 2025 | marketbeat.comImmunic raises $65M in public offering to fund clinical trialsJune 3, 2025 | proactiveinvestors.comImmunic raises $65M in public offering to fund clinical trialsJune 3, 2025 | proactiveinvestors.comImmunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public OfferingJune 3, 2025 | prnewswire.comImmunic to Participate in Investor, Scientific and Industry Conferences in JuneJune 2, 2025 | prnewswire.comD. Boral Capital Issues Pessimistic Forecast for Immunic (NASDAQ:IMUX) Stock PriceMay 31, 2025 | americanbankingnews.comD. Boral Capital Cuts Immunic (NASDAQ:IMUX) Price Target to $10.00D. Boral Capital reduced their price target on shares of Immunic from $17.00 to $10.00 and set a "buy" rating on the stock in a research report on Thursday.May 30, 2025 | marketbeat.comImmunic announces public offering of warrants to fund trialsMay 30, 2025 | investing.comImmunic shares fall 12% after pricing of $65 million underwritten public offering to fund trialsMay 29, 2025 | msn.comImmunic unveils pricing of $65M underwritten public offeringMay 29, 2025 | proactiveinvestors.comImmunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public OfferingMay 29, 2025 | prnewswire.comImmunic, Inc. Announces Proposed Public OfferingMay 28, 2025 | prnewswire.comImmunic (NASDAQ:IMUX) Receives Buy Rating from B. RileyB. Riley reiterated a "buy" rating and issued a $5.00 target price (down from $6.00) on shares of Immunic in a report on Friday.May 25, 2025 | marketbeat.comImmunic Analyst Ratings and Price Targets | NASDAQ:IMUX | BenzingaMay 24, 2025 | benzinga.comJanus Henderson Group PLC Cuts Stock Holdings in Immunic, Inc. (NASDAQ:IMUX)Janus Henderson Group PLC lowered its holdings in Immunic, Inc. (NASDAQ:IMUX - Free Report) by 47.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,689,082 shares of the company's stock after selling 2,410,196 shares duriMay 23, 2025 | marketbeat.comImmunic, Inc. (NASDAQ:IMUX) Given Average Rating of "Buy" by AnalystsImmunic, Inc. (NASDAQ:IMUX - Get Free Report) has been assigned an average rating of "Buy" from the eight ratings firms that are currently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to theMay 19, 2025 | marketbeat.comImmunic (IMUX) Expected to Announce Quarterly Earnings on WednesdayImmunic (NASDAQ:IMUX) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 14. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-14-immunic-inc-stock/)May 9, 2025 | marketbeat.comWilliam Blair Analysts Boost Earnings Estimates for ImmunicImmunic, Inc. (NASDAQ:IMUX - Free Report) - Equities researchers at William Blair lifted their FY2025 EPS estimates for Immunic in a research report issued on Wednesday, April 30th. William Blair analyst M. Minter now expects that the company will post earnings of ($0.86) per share for the year,May 6, 2025 | marketbeat.comLeerink Partnrs Has Bullish Estimate for Immunic Q2 EarningsImmunic, Inc. (NASDAQ:IMUX - Free Report) - Leerink Partnrs boosted their Q2 2025 EPS estimates for shares of Immunic in a research note issued to investors on Wednesday, April 30th. Leerink Partnrs analyst F. Khurshid now forecasts that the company will earn ($0.16) per share for the quarter, upMay 6, 2025 | marketbeat.comResearch Analysts Issue Forecasts for Immunic Q1 EarningsImmunic, Inc. (NASDAQ:IMUX - Free Report) - Equities researchers at William Blair issued their Q1 2025 earnings per share estimates for Immunic in a research report issued on Wednesday, April 30th. William Blair analyst M. Minter anticipates that the company will earn ($0.25) per share for the quMay 4, 2025 | marketbeat.comImmunic (NASDAQ:IMUX) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Immunic in a research note on Thursday.May 3, 2025 | marketbeat.comImmunic Reports Positive Data From Phase 2 CALLIPER Study Of Vidofludimus CalciumMay 2, 2025 | nasdaq.comD. Boral Capital Reiterates "Buy" Rating for Immunic (NASDAQ:IMUX)D. Boral Capital restated a "buy" rating and issued a $17.00 price target on shares of Immunic in a research report on Wednesday.May 2, 2025 | marketbeat.comImmunic to Participate in Scientific and Industry Conferences in MayMay 2, 2025 | prnewswire.comImmunic, Inc. (NASDAQ:IMUX) Shares Sold by Adage Capital Partners GP L.L.C.Adage Capital Partners GP L.L.C. cut its position in shares of Immunic, Inc. (NASDAQ:IMUX - Free Report) by 75.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,398,600 shares of the company's stock after selling 4May 2, 2025 | marketbeat.comImmunic drops after mid-stage trial data for multiple sclerosis drugMay 1, 2025 | msn.comImmunic reports reduced disability worsening in progressive multiple sclerosis trialApril 30, 2025 | proactiveinvestors.comImmunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER TrialApril 30, 2025 | prnewswire.comImmunic: A Strong Buy With Imminent Data Readout That Should Send Shares HigherApril 28, 2025 | seekingalpha.comOne Immunic Insider Raised Their Stake In The Previous YearApril 25, 2025 | finance.yahoo.comImmunic, Inc. (NASDAQ:IMUX) Receives Average Recommendation of "Buy" from BrokeragesImmunic, Inc. (NASDAQ:IMUX - Get Free Report) has earned a consensus rating of "Buy" from the eight brokerages that are covering the company, MarketBeat reports. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1-year pApril 24, 2025 | marketbeat.comEquities Analysts Set Expectations for Immunic Q1 EarningsImmunic, Inc. (NASDAQ:IMUX - Free Report) - Stock analysts at B. Riley raised their Q1 2025 EPS estimates for Immunic in a research report issued on Wednesday, April 16th. B. Riley analyst W. Wood now forecasts that the company will post earnings per share of ($0.26) for the quarter, up from theiApril 20, 2025 | marketbeat.comFY2025 Earnings Estimate for Immunic Issued By HC WainwrightImmunic, Inc. (NASDAQ:IMUX - Free Report) - HC Wainwright lifted their FY2025 EPS estimates for shares of Immunic in a research note issued on Tuesday, April 15th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings of ($0.77) per share for the year, up from theirApril 19, 2025 | marketbeat.comImmunic, Inc. Common Stock (IMUX)April 18, 2025 | nasdaq.comB. Riley Reaffirms "Buy" Rating for Immunic (NASDAQ:IMUX)B. Riley reissued a "buy" rating and set a $6.00 price target on shares of Immunic in a report on Wednesday.April 18, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for Immunic Q1 Earnings?Immunic, Inc. (NASDAQ:IMUX - Free Report) - HC Wainwright issued their Q1 2025 EPS estimates for shares of Immunic in a note issued to investors on Tuesday, April 15th. HC Wainwright analyst M. Caufield expects that the company will earn ($0.26) per share for the quarter. HC Wainwright currentlyApril 18, 2025 | marketbeat.comImmunic (NASDAQ:IMUX) Earns Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $10.00 price target on shares of Immunic in a research note on Tuesday.April 17, 2025 | marketbeat.comEQS-News: Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen InvestmentsApril 10, 2025 | markets.businessinsider.comImmunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen InvestmentsApril 10, 2025 | prnewswire.comEQS-News: Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen InvestmentsApril 10, 2025 | markets.businessinsider.comImmunic sells 5.67M shares at 90c in registered direct offeringApril 10, 2025 | markets.businessinsider.comImmunic announces pricing of $5.1M direct offering to support clinical pipelineApril 9, 2025 | proactiveinvestors.com Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Email Address IMUX Media Mentions By Week IMUX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMUX News Sentiment▼0.800.68▲Average Medical News Sentiment IMUX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMUX Articles This Week▼154▲IMUX Articles Average Week Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Astria Therapeutics News Terns Pharmaceuticals News Alpha Teknova News Rocket Pharmaceuticals News Aura Biosciences News Ocugen News UroGen Pharma News Entrada Therapeutics News Allogene Therapeutics News Cidara Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMUX) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump Nominates “Next Elon”Elon's Replacement? You've been told Elon Musk has been forced out of DC. But did you know his successor ha...Altimetry | SponsoredGet Ready for Elon Musk’s BIGGEST Comeback YetTesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMUX Stock Free IMUX Stock Alerts